Delving into the Latest Updates on JYP-0035 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid NeoplasmSolid tumor

Inactive Indication-

Originator Organization

Jiayue (Chengdu) Pharmaceutical Technology Co., Ltd.

Active Organization

Jiayue (Chengdu) Pharmaceutical Technology Co., Ltd.

Guangzhou Jiayue Pharmaceutical Technology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The goal of this Phase I clinical trial is to evaluate the safety, tolerability, and pharmacokinetic characteristics of the JYP0035 capsule in patients with advanced solid tumors. The main questions it aims to answer are:
* What is the safety profile of JYP0035 when administered to these patients?
* How does JYP0035 capsule behave in the body pharmacokinetically?
Participants will:
* Receive escalating doses of JYP0035 capsule during the dose-escalation phase (PART-1).
* Continue with the identified dose in the dose-expansion phase (PART-2).
As this is a single-arm study, there is no comparison group.

Start Date01 Jan 2024

Sponsor / Collaborator

Jiayue (Chengdu) Pharmaceutical Technology Co., Ltd.

[+1]

100 Clinical Results associated with JYP-0035

Login to view more data

100 Translational Medicine associated with JYP-0035

Login to view more data

100 Patents (Medical) associated with JYP-0035

Login to view more data

100 Deals associated with JYP-0035

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	CN	Guangzhou Jiayue Pharmaceutical Technology Co., Ltd.	01 Jan 2024
Solid tumor	Phase 1	CN	Jiayue (Chengdu) Pharmaceutical Technology Co., Ltd.	04 Dec 2023